Hyperglycemia contributes to the pathogenesis of neuropathy in both type 1 and type 2 diabetes. Other metabolic and vascular factors, particularly hypertriglyceridemia, are important.
The clinical presentation comprises a broad constellation of symptoms and deficits, involving sensory, motor, and autonomic nerve fibers, and multiple organ systems.
Diabetic peripheral neuropathy is the most common chronic complication of diabetes, characterized by the presence of peripheral nerve dysfunction, diagnosed after the exclusion of other causes. Pain is the outstanding complaint in most patients, but many patients are completely asymptomatic.
Treatment has traditionally focused on control of hyperglycemia as a means of slowing progression or delaying onset, on targeting potential pathogenetic mechanisms, and on pain reduction.
Although pain is generated principally by peripheral nerve injury, there is recent evidence the central nervous system may play a significant role in the disinhibition and amplification of pain. Indeed, the most effective drugs in treating painful diabetic neuropathy are centrally acting. Pregabalin (a voltage-gated calcium channel modulator), duloxetine (a selective dual serotonin-norepinephrine reuptake inhibitor), and tapentadol (an agonist of the mu-opioid receptor and norepinephrine reuptake inhibitor) are the only prescription drugs currently approved for treating painful diabetic neuropathy in some countries.
Diabetic neuropathy (DN) is a highly prevalent complication of diabetes (type 1 or type 2) and is characterized by the presence of symptoms and/or signs of peripheral nerve dysfunction and/or autonomic nerve dysfunction. It is diagnosed after the exclusion of other causes. Frequently, however, people with DN are asymptomatic.
Professor of Medicine
Organizational Official for the Human Research Protection Program
Weill Cornell Medicine - Qatar
RAM is on speaker panels for Eli Lilly, Novo Nordisk, and Pfizer; he is on advisory boards for Novo Nordisk and Pfizer. RAM is an author of a number of references cited in this monograph.
Speciality Registrar in Diabetes & Endocrinology and General Internal Medicine
University of Manchester
UA serves on advisory boards for Eli Lilly.
SpR Diabetes and Endocrinology
Diabetes and Endocrinology
University of Manchester
SA declares that she has no competing interests.
Dr Rayaz Malik, Dr Uazman Alam, and Dr Shazli Azmi would like to gratefully acknowledge Dr Rodica Pop-Busui and Dr Eva Feldman, the previous contributors to this monograph. RPB declares that she has received speaking honoraria from Pfizer and research support from Amylin Pharmaceuticals; National Institutes of Health/National Heart, Lung, and Blood Institute; National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases; American Diabetes Association; and Juvenile Diabetes Research Foundation. RPB is an author of several references cited in this monograph. EF is an author of a number of references cited in this monograph.
Department of Medicine
Mount Sinai School of Medicine
ZTB declares that he has no competing interests.
Assistant Professor of Medicine
Harvard Medical School
Division of Endocrinology
Diabetes and Hypertension
Brigham and Women's Hospital
RKG has received consultant fees from Aventis and Novartis, and speaker fees from Novartis.
Consultant and Honorary Senior Lecturer
Tameside General Hospital
Ashton Under Lyne
EJ has received funding for conferences and lectures from Pfizer and Boehringer Ingelheim.
Use of this content is subject to our disclaimer